A study of very low dose twice-daily compared to standard low dose once-daily aspirin following acute coronary syndromes - WILL lOWer dose aspirin be more effective following ACS? - WILLOW-ACS - Version 1

Overview

No summary available.

Registry

who.int

Start Date

June 28, 2018

End Date

March 30, 2017

Last Updated

7 years ago

Study Type

Interventional clinical trial of medicinal product

Sponsor

•For inclusion in the study, subjects should fulfil the following criteria:
•1\.Provision of informed consent prior to any study specific procedures
•2\.Male or female aged greater than 18 years
•3\.Previous diagnosis of acute coronary syndrome greater than 30 days and less than 10 months before enrolment
•4\.Receiving dual antiplatelet therapy with aspirin 75 mg once daily and ticagrelor 90 mg twice daily
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1\.2 Adults (18\-64 years) yes
•F.1\.2\.1 Number of subjects for this age range 6
•F.1\.3 Elderly (\>\=65 years) yes

•1\.Presence of an indication for dual antiplatelet therapy other than ischaemic heart disease
•2\.PCI with drug eluting or bare metal stent(s) within 30 days of randomization
•3\.Any history of stent implantation to the left main coronary artery
•4\.Any history of stent thrombosis during dual antiplatelet therapy
•5\.Planned procedure for coronary revascularization
•6\.Any planned surgery or other procedure that may require suspension or discontinuation of dual antiplatelet therapy expected to occur within 3 months of randomisation
•7\.Prior intention by patient or physician to discontinue aspirin and/or ticagrelor within the study period
•8\.Receiving doses of aspirin and ticagrelor other than 75 mg once daily and 90mg twice daily respectively
•9\.Treatment or planned treatment with antiplatelet medication apart from aspirin or ticagrelor (eg. clopidogrel, prasugrel, dipyridamole, ticlopidine).
•10\.Current use of a loop, thiazide or potassium sparing diuretic (affects prostanoid assays).